Mabwell's 9MW2821, a Nectin-4-targeting antibody-drug conjugate, demonstrated an 83% objective response rate in combination with toripalimab for locally advanced or metastatic urothelial carcinoma, with a confirmed response rate of 74.5% and median progression-free survival of 12.9 months. Early-stage perioperative data in muscle-invasive bladder cancer showed a 66.7% pathological complete response rate with acceptable tolerability, positioning this agent as a multi-indication candidate in genitourinary and gynecologic malignancies.
Key Points
- 83% objective response rate; 74.5% confirmed ORR in urothelial carcinoma combination trial
- 12.9-month median progression-free survival; no new safety signals with dual therapy
- 66.7% pathological complete response in perioperative bladder cancer phase II cohort
Longevity Analysis
This immunotherapy approach targets a mechanism of tumor immune evasion through Nectin-4 blockade combined with checkpoint inhibition, representing a therapeutic strategy that engages the body's own defense mechanisms to recognize and eliminate dysregulated cells. The durable response profiles and early complete remission data suggest sustained immune engagement rather than transient cytotoxic effect. For patients with advanced or treatment-naive disease, achieving disease control and complete responses before standard surgical resection broadens the window for curative intent and potentially reduces disease burden that would otherwise compromise post-treatment recovery and long-term survival outcomes.
Original published by LT Wire.